Fatty liver reexamined choline and mitochondrial toxin amelioration

Table 6 Mechanisms of action for the proposed therapeutic strategy¹

Mechanism	Description	Therapeutic outcome
Enhancing PC via choline supplementation	Utilizes delivery of choline to augment PC biosynthesis via the cytidine diphosphate-choline and PEMT pathways	Increases VLDL assembly, improves hepatic lipid export, reduces intracellular triglyceride accumulation
Reducing mitochondrial toxins (linoleic acid and ethanol)	Minimizes exposure to linoleic acid and ethanol, reducing formation of 4-hydroxynonenal and acetaldehyde	Decreases mitochondrial damage, preserves electron transport chain function, and improves adenosine triphosphate production

¹This table outlines the dual mechanisms of a novel therapeutic approach for fatty liver disease. First, choline delivery enhances phosphatidylcholine synthesis via the cytidine diphosphate-choline and PEMT pathways, boosting verylowdensity lipoprotein assembly and reducing hepatic triglyceride levels by up to 30%, as evidenced in preclinical models. Second, minimizing mitochondrial toxins—such as linoleic acid and ethanol—decreases reactive aldehyde formation (e.g., 4-hydroxynonenal), thereby preserving β-oxidation and mitochondrial integrity. This strategy integrates decades of lipid metabolism research, offering a comprehensive approach to restore hepatic function.

PC: Phosphatidylcholine; VLDL: Verylowdensity lipoprotein.